Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Assets: 2022-2025

Historic Current Assets for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $565.3 million.

  • Axsome Therapeutics' Current Assets rose 18.00% to $565.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.3 million, marking a year-over-year increase of 18.00%. This contributed to the annual value of $485.1 million for FY2024, which is 3.81% down from last year.
  • Per Axsome Therapeutics' latest filing, its Current Assets stood at $565.3 million for Q3 2025, which was up 5.35% from $536.6 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Current Assets ranged from a high of $565.3 million in Q3 2025 and a low of $86.8 million during Q1 2022.
  • For the 3-year period, Axsome Therapeutics' Current Assets averaged around $484.0 million, with its median value being $494.6 million (2025).
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 399.81% in 2023, then dropped by 10.90% in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Current Assets stood at $245.6 million in 2022, then soared by 105.28% to $504.3 million in 2023, then fell by 3.81% to $485.1 million in 2024, then grew by 18.00% to $565.3 million in 2025.
  • Its Current Assets was $565.3 million in Q3 2025, compared to $536.6 million in Q2 2025 and $494.6 million in Q1 2025.